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Abstract
Background: Presenilin-1 (PS1), the active component of the intramembrane γ-secretase complex, can be detected
as soluble heteromeric aggregates in cerebrospinal fluid (CSF). The aim of this study was to examine the different
soluble PS1 complexes in the lumbar CSF (CSF-PS1) of individuals with Alzheimer’s disease (AD), particularly in both
symptomatic and asymptomatic genetically determined AD, in order to evaluate their potential as early biomarkers.
Methods: Western blotting, differential centrifugation and co-immunoprecipitation served to determine and
characterize CSF-PS1 complexes. We also monitored the assembly of soluble PS1 into complexes in a cell model,
and the participation of Aβ in the dynamics and robustness of the stable PS1 complexes.
Results: There was an age-dependent increase in CSF-PS1 levels in cognitively normal controls, the different
complexes represented in similar proportions. The total levels of CSF-PS1, and in particular the proportion of the
stable 100–150 kDa complexes, increased in subjects with autosomal dominant AD that carried PSEN1 mutations
(eight symptomatic and six asymptomatic ADAD) and in Down syndrome individuals (ten demented and ten non-
demented DS), compared with age-matched controls (n = 23), even prior to the appearance of symptoms of
dementia. The proportion of stable CSF-PS1 complexes also increased in sporadic AD (n = 13) and mild-cognitive
impaired subjects (n = 12), relative to age-matched controls (n = 17). Co-immunoprecipitation demonstrated the
association of Aβ oligomers with soluble PS1 complexes, particularly the stable complexes.
Conclusions: Our data suggest that CSF-PS1 complexes may be useful as an early biomarker for AD, reflecting the
pathology at asymptomatic state.
Keywords: Presenilin-1, Cerebrospinal fluid, Biomarker, Pre-symptomatic, Autosomal dominant Alzheimer’s disease,
Down syndrome, Mild-cognitive impairment
Background
Alzheimer’s disease (AD) is a progressive neurodegener-
ative disorder that involves a gradual decline in memory
and other cognitive functions, representing the most
common cause of dementia in the elderly. Apart from
the common late-onset forms of sporadic AD (sAD),
rare mutations in the genes encoding the β-amyloid pre-
cursor protein (APP; chromosome 21q21), presenilin-1
(PSEN1; chromosome 14q24.3) and presenilin-2 (PSEN2;
chromosome 1q31-q42) cause autosomal dominant AD
(ADAD; also named as familial AD or FAD) [1]. ADAD
exhibits similar phenotype as sAD but with an earlier
clinical onset. The APP gene encodes a large type I
transmembrane protein that upon proteolytic processing
[2] can generate the β-amyloid peptide (Aβ), the major
constituent of senile plaques and the triggering effector
of AD. In the amyloidogenic pathway the Aβ peptide is
generated by sequential cleavage of APP, starting with
the cleavage of the large extracellular domain by the β-
secretase cleaving enzyme (BACE1), which is followed by
the successive action of γ-secretase at the membrane-
spanning domain [3]. This γ-secretase is an intramembrane
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protease complex composed of presenilin-1 (PS1), nicastrin,
APH1 (anterior pharynx-defective 1) and PEN2 (presenilin
enhancer 2) [4]. PS1 is the catalytic subunit of the γ-
secretase complex [5]. Duplications of APP and neighbor-
ing sequences are also linked to an early age of AD onset
[6]. As such, Down’s syndrome (DS) is also associated with
the development of AD since the APP gene lies on chromo-
some 21, and the extra copy leads to Aβ over-expression.
Accordingly, most DS patients who live beyond the age of
40 years develop typical brain neuropathology AD and a
significant proportion develop additional cognitive decline
[7–9]. Thus, both these disease conditions, ADAD and DS,
can be considered as early-onset forms of genetically deter-
mined AD [10].
Classic biomarkers, total and phospho-tau, as well as
Aβ42, have shown diagnostic accuracy for incipient AD
[11]. However total and phospho-tau also increased as a
result of other neurological processes; while levels of the
pathological Aβ42 species, which increased in the AD
brain, resulted decreased in CSF due to increasing
deposition, hindering the interpretation of changes in
their soluble levels in early stages. Thus, there is still a
need to identify additional early biomarkers. We recently
demonstrated the presence of heteromeric PS1 com-
plexes in human CSF (CSF-PS1) and serum, and that
increases in the proportion of stable CSF-PS1 complexes
served to discriminate sAD from non-disease controls
[12]. PS1 is known to undergo endoproteolytic cleavage
as part of its maturation, generating N- and C-terminal
fragments (NTF and CTF) of about 29 and 20 kDa, re-
spectively [13]. Both, the NTF and CTF of PS1 contain
several transmembrane domains [14]; and our earlier
data indicated that PS1 fragments might be highly un-
stable in CSF and serum, and that they spontaneously
form complexes due to the large number of hydrophobic
regions. Indeed, we demonstrated the presence of stable
100–150 kDa heteromeric complexes in CSF that
contained the NTF and CTF of PS1 (maybe also involv-
ing other γ-secretase components), as well other large
complexes. Some of these complexes were unstable
under denaturing conditions and resolved as ~50 kDa
heterodimers upon electrophoresis [12]. Moreover, an
increase in the proportion of stable 100–150 kDa com-
plexes appears to be a good marker to discriminate
pathological AD samples from controls.
As such, we set out to further characterize these
soluble PS1 complexes and the involvement of oligo-
meric Aβ in the formation of these complexes. We also
evaluated the possibility that the proportions and nature
of the CSF-PS1 complexes may vary during aging. The
main interest was to investigate the levels of CSF-PS1
complexes in ADAD, sAD and DS, particularly in AD
and DS subjects who had not yet developed dementia,
including also mild-cognitive impaired (MCI) subjects.
Thereby, we attempt to determine whether alterations to
the levels of these complexes might reflect the patho-
logical state at early, asymptomatic stages. Using a
collection of well-characterized CSF samples from sAD
PS1 complexes were also analyzed. Genetically deter-
mined AD offers unique opportunities to analyze diag-
nostic biomarkers at asymptomatic stages, particularly
given that only in this group is a diagnosis guaranteed
for the early comparison of biomarkers.
Methods
Patients
Lumbar CSF samples were obtained from ADAD subject
that were all carriers of PSEN1 mutations and who were
part of the Genetic Counseling Program (PICOGEN) at
the Hospital Clínic, Barcelona [15]. This group included
14 subjects carrying PSEN1 mutations (including six
asymptomatic mutation carriers), and eight age-matched
non-mutation carriers from the same families (younger
non-disease controls: yNC). The clinical and CSF data of
some of these patients has been reported previously [16,
17]. We also included lumbar CSF samples from 10 DS
subjects with Alzheimer’s type dementia (dDS) and 10
DS subjects without signs of memory decline (ndDS)
obtained at the Hospital Sant Pau, Barcelona, along with
15 additional age-matched yNC obtained from both
hospitals. In addition, 15 patients with dementia due to
sAD, 12 subjects with MCI and 17 age-matched elderly
controls (eNC) were also obtained from the Hospital
Sant Pau, Barcelona. See Table 1 for details of clinical
and demographic data. All AD patients fulfilled the
2011 NIA-AA criteria for dementia or MCI due to AD
[18, 19], while discrimination between the dDS sub-
jects and those without dementia was assessed using
the modified Cued Recall Test and the CAMDEX-DS
battery [20, 21]. All the control subjects had no his-
tory or symptoms of neurological or psychiatric disor-
ders, or memory complaints. This study was approved
by the ethics committee at the Miguel Hernandez
University and it was carried out in accordance with
the Declaration of Helsinki.
PS1 over-expressing cells silencing by siRNA
CHO cells (400,000 cells/well) were grown in DMEM®
(Gibco) containing 10 % Fetal Bovine Serum (Gibco)
and 1 % Penicillin/Streptomycin (Sigma-Aldrich), and
they were transfected with a construct encoding full-
length PS1 (2 μg cDNA) [22] or with the pcDNA3 ex-
pression plasmid alone (Invitrogen), using Lipofectamine
2000® (Invitrogen). To reduce the PS1 gene expression
we used CHO cells stably over expressing wild-type hu-
man PS1 and APP (CHO-PS1/APP) [23]. CHO-PS1/APP
cells (350,000 cells/well) were grown in DMEM® contain-
ing 10 % Fetal Bovine Serum, 0,1 % Puromicin (Sigma-
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Aldrich) and 0,2 % G418 disulfate salt (Sigma-Aldrich),
were transfected with BLOCK iT™ Alexa Fluor® Red Fluor-
escent Oligo (Invitrogen) as control, or siRNA (50 nM)
targeting human PS1 (Santa Cruz Biotechnology, INC).
Without removing the cell media, 24 h after the first
transfection cells were transfected with the same siRNA
(30 nM) and incubated for an additional 18 h.
Western blotting and immunoprecipitation
Although the denaturation temperature prior to elec-
trophoresis has not been standardized, we found that
high temperature sample preparation for electrophor-
esis (98 °C) produced an overall loss of CSF-PS1 im-
munoreactivity [24]. Hence, all analyses of in this
study PS1 avoided freeze-thaw cycles (samples were
aliquoted), and denaturation prior to electrophoresis
was conducted at 50 °C.
Samples (30 μL for CSF) were resolved by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) under reducing conditions. The proteins were
then transferred to nitrocellulose membranes (Schleicher
and Schuell Bioscience GmbH) that were probed with
PS1 antibodies directed against the N-terminal amino
acids 1–20 (antibody 98/1) [24]. GAPDH (Abcam)
served as a loading control for cellular extracts. Mem-
branes were incubated with the corresponding horserad-
ish peroxidase conjugated secondary antibody and the
immunoreactive signal was detected in a Luminescent
Image Analyzer LAS-1000 Plus (FUJIFILM) using Super-
Signal West Dura Extended Duration Substrate (Thermo
Scientific). A control CSF sample was used to normalize
the immunoreactive signal, and for semi-quantitative
studies the intensity of the immunoreactive bands was
measured by densitometry using Science Lab Image
Gauge v 4.0 software provided by FUJIFILM. Aβ
peptides in CSF immunoprecipitates (see below) were
resolved by 16 % Tris-tricine SDS-PAGE and detected
with the 6E10 antibody (Covance Research).
For immunoprecipitation, samples were precleared for
2 h at 4 °C by incubation with protein A-Sepharose
(Sigma-Aldrich). Immunoprecipitations were performed
at 4 °C by incubating 150 μL of CSF or cell media, over-
night with the primary PS1 C-terminal antibody 00/2
(raised against residues 301–317) [23] previously
coupled to protein A-Sepharose using Dimethyl pimeli-
midate dihydrochloride (Sigma-Aldrich Co). Precipitated
proteins were washed with PBS and eluted with 0.1 M
glycine buffer at pH 2.5. After pH neutralization, super-
natants were denatured in Laemmli sample buffer at 50 °
C for 15 min and subjected to SDS-PAGE. The mem-
branes were then probed with anti-PS1 (98/1) and anti-
Aβ (6E10) antibodies.
Sucrose gradients
PS1 complexes were analyzed by ultracentrifugation for 4 h
at 4 °C on a continuous sucrose density gradient (5–20 %)
at 250,000 × g. CSF aliquots (65 μL) were carefully loaded
onto the top of the gradient containing 2 mL of 0.15 M
NaCl, 50 mM MgCl2 and 0.5 % Brij 97 in 50 mM Tris-HCl
(pH 7.4). After centrifugation, ~14 fractions were collected
gently from the top of the tubes. Enzyme markers of known
sedimentation coefficient, β-galactosidase, catalase and al-
kaline phosphatase were used in the gradients to determine
the approximate sedimentation coefficients. The sucrose
fractions containing highly stable and unstable PS1 com-
plexes were pooled separately, dialyzed against Tris buffer
Table 1 Clinical, demographic data and classic CSF biomarker levels
Group Age (years) n (Gender) MMSE score CSF Aβ42 (pg/mL) CSF T-tau (pg/mL) CSF P-tau (pg/mL)
yNC
{yNC member of the
same ADAD families}
45 ± 2 [25–60]
{37 ± 3 [25–47]}
n = 23 (15 F/8 M)
{6 F/2 M}
29 ± 1 [25–30]







syADAD 45 ± 3 [31–59] n = 8 (5 F/3 M) 21 ± 2* [11–28] 300 ± 54* 899 ± 186* 164 ± 60*
psADAD 36 ± 3 [24–41] n = 6 (4 F/2 M) 30 ± 1 [29, 30] 1120 ± 252 222 ± 26 49 ± 5
dDS 55 ± 2 [43–61] n = 10 (5 F/5 M) ND 411 ± 24* 788 ± 125*,a 106 ± 14*,a
ndDS 43 ± 2 [33–49] n = 10 (5 F/5 M) ND 570 ± 51* 232 ± 53 45 ± 8
eNC 67 ± 1 [61–80] n = 17 (11 F/6 M) 29 ± 1 [26–30] 753 ± 30 197 ± 12 42 ± 2
sAD 68 ± 2 [54–83] n = 13 (9 F/4 M) 20 ± 1** [18–24] 351 ± 17** 833 ± 87** 135 ± 18**
MCI due to AD 66 ± 1 [61–72] n = 12 (5 F/7 M 26 ± 1** [20–30] 422 ± 31 618 ± 66** 81 ± 8**
In the yNC group (younger controls), the values for the control subgroup of non-mutation carriers from the same families as the carriers of PSEN1 mutations are
also indicated; the rest of cases correspond to subject without family history of ADAD. The PSEN1 mutations included in this study from syADAD cases (“symptomatic”
autosomal dominant AD subjects) corresponded to 3 carriers of L286P, and one of I439S, S169P, L173F, L235R and L282R. Those psADAD subjects (pre-symptomatic
subjects carrying mutations in PSEN1) were 3 carriers of M139T, and one of I439S, R220G and K239N. Patients with (dDS) or without (ndDS) signs of clinical dementia
were also compared with yNC; sporadic AD (sAD) and mild-cognitive impaired (MCI) subjects were compared with elderly controls (eNC). Levels of Aβ42, T-tau and
P-tau were determined by ELISA; the intra-assay coefficient of variability (CV) was below 5 % and inter-assay CV below 15 % for all the classical AD biomarkers, in
agreement with previous reports [36]. The number of samples “n” for female (F) and male (M) subjects is indicated. The data represent the means ± SEM, and for age
and MMSE (Minimental State Examination), the range of values is also indicated. *Significantly different (p <0.05) from the yNC group, aand from the ndDS group;
**Significantly different (p <0.05) from the eNC group
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and concentrated by ultrafiltration (Amicon Ultra 10,000
MWCO, Millipore Corporation, Bedford, MA). The PS1
complexes were then immunoprecipitated with anti-PS1
00/2 as described.
Measurement of T-tau, P-tau and Aβ42 by ELISA
The CSF levels of total tau (T-tau), phosphorylated tau
(P-tau) and Aβ1-42 (Aβ42) were determined using
specific enzyme-linked immunosorbent assays (ELISA:
Fujirebio Europe, Ghent, Belgium).
Statistical analysis
All data were analyzed using SigmaStat (Version 3.5; Sys-
tac Software Inc.), applying a one-way analysis of variance
or a Kruskal-Wallis test when the hypothesis of equality of
sample variances was rejected. Pairwise group compari-
sons were then sustained using Student t test (two-tailed)
or Mann-Whitney U test, and the exact p values deter-
mined. The results are presented as the means ± SEM,
and correlations between the variables were assessed by
linear regression analyses, with p values <0.05 considered
statistically significant.
Results
The increase in CSF-PS1 with age
Since the main aim of the present study was to determine
the changes in CSF-PS1 associated with ADAD and DS,
and given that both ADAD and DS exhibits earlier clinical
onset, we first assessed whether the amount and nature of
the soluble PS1 complexes varies with age. The PS1 com-
plexes in samples from control subjects (NC) from 25 to
80 years-of-age were detected with the 98/1 antibody,
which predominantly recognized complexes of approxi-
mately 100 and 150 kDa, together with a less abundant
50 kDa band (Fig. 1a). The identity of these bands as com-
plexes involving NTF- and CTF-PS1 was demonstrated in
a previous study [12]. This soluble 50 kDa PS1 band may
represent a NTF and CTF-PS1 aggregate, as the holopro-
tein had a mass of ~43 kDa and it differs in its electrophor-
etic migration [12]. PS1-NTF monomers are not detectable
in human CSF samples. Since ADAD starts prior to 60 years
of age [1], we sub-grouped young and elderly NC below
and above this threshold. The sum of the immunoreactivity
for the major 100 and 150 kDa PS1 complexes was signifi-
cantly higher (~58 %) in the elderly NC (eNC; n = 18) than
in the young NC samples (yNC; n = 19; p <0.001: Fig. 1b).
No differences were found between values obtained from
the two center of sample collection. In all the NC samples,
the major 100 and 150 kDa PS1 complexes were positively
correlated with age (r = 0.54; p <0.001: Fig. 1c). Therefore,
this age-dependent increase in PS1 complexes must be
taken into account when comparing the different patho-
logical groups with non-disease subjects, defining appropri-
ate age-matched controls.
We also attempted to assess potential differences in
the class of the PS1 complexes in the NC sub-groups
based on the direct analysis of the Western blots. As
such, we defined the (100 + 150 kDa)/50 kDa quo-
tient for each sample. No change was observed in
the (100 + 150 kDa)/50 kDa quotient evaluated in CSF
from yNC and eNC subjects (Fig. 1b).
Higher PS1 levels in symptomatic and asymptomatic
ADAD
To assess whether the amount of CSF-PS1 is altered in
ADAD, the levels in the age-matched yNC group were
compared with those in the CSF from symptomatic
(syADAD) and asymptomatic (pre-symptomatic: psA-
DAD) subjects carrying mutations in PSEN1 in Western
blots (see Table 1 and Fig. 2a). Stronger immunorea-
ctivity for the 100 and 150 kDa complexes was evident
in syADAD (~119 %; p <0.001) and in psADAD (~87 %;
p <0.001) subjects compared to the yNC, with no differ-
ences between the two pathological groups (Fig. 2b).
Indeed, the levels in these AD subjects were significantly
higher than in the yNC sub-group, composed by
non-mutation carriers from the same ADAD families
(p <0.001). The previously defined quotient of CSF-
PS1 complexes (see above) also discriminated be-
tween the yNC and the two ADAD groups, both
individually (p = 0.007 for syADAD; p = 0.027 for
psADAD) or when considered as a unique patho-
logical group (p = 0.007). Thus, a higher proportion
of 100 + 150 kDa CSF-PS1 complexes appears to be
associated with ADAD even at pre-symptomatic
stages (Fig. 2b).
PS1 complexes can be also characterized by gradient
ultracentrifugation [24], followed by Western blotting
under denaturing conditions, which served to illustrate
the existence of different CSF-PS1 complexes [12].
When, CSF-PS1 complexes from yNC and syADAD
subjects were characterized by sedimentation analysis on
sucrose density gradients (Fig. 2c), 100–150 kDa PS1
complexes were identified close to the alkaline phos-
phatase marker (~140–160 kDa), along with larger
complexes that sedimented in regions closer to the cata-
lase marker (~232 kDa). These latter complexes were
unstable and resolved as 50 kDa peptides by SDS-PAGE/
Western blot analysis (Fig. 2c). In good agreement with
results with the CSF-PS1 complex quotient obtained for
direct Western blot analysis, samples separated by ultra-
centrifugation revealed higher abundance of the highly
stable 100–150 kDa PS1 complexes in the syADAD
samples than in the yNC samples, more so than the
complexes of the 50 kDa fragments that sedimented in
the denser fractions. This difference was clearly evident
with the determination of a refined quotient, the “sta-
bility” quotient, reflecting the differences between the
Sogorb-Esteve et al. Molecular Neurodegeneration  (2016) 11:66 Page 4 of 11
highly stable complexes (the 100–150 kDa heterodimers
that sediment close to the internal marker of similar mo-
lecular mass) and the unstable complexes (the 50 kDa
complexes that sediment closer to catalase), this quo-
tient allowing us to discriminate syADAD (p = 0.004)
from yNC samples (Fig. 2d).
Highly stable CSF-PS1 complexes are elevated in sAD and
MCI
In sAD no notable differences in total PS1 were ob-
served between patients with dementia due to sAD, MCI
due to AD, or age-matched eNC subjects (Fig. 3a, b).
However, the highly stable PS1 complexes were again
more abundant in probable sAD cases compared to eld-
erly eNCs when the CSF-PS1 complexes quotient was
calculated (p = 0.006; Fig. 3b). Sucrose density centrifu-
gation profiles (Fig. 3c) and the subsequent estimation of
the “stability” quotient confirmed the greater abundance
of highly stable PS1 complexes in sAD compared to
eNC (p = 0.02; Fig. 3d), as well as indicating that the
highly stable complexes were particularly increased in
MCI subjects (p = 0.008; Fig. 3d).
Fig. 1 Characterization of the CSF-PS1 complexes in younger and elderly NC subjects, and their correlation with age. a Representative
Western blots of human CSF samples from non-demented control (NC) subjects arbitrarily categorized as young (yNC; ≤60 years; n = 23)
and elderly (eNC; >60 years; n = 17), and probed with an anti-NTF-PS1 antibody. b Densitometric quantification of the major 100 and
150 kDa CSF-PS1 complexes (the sum of the 100 + 150 kDa CSF-PS1 bands) and the quotient derived from the immunoreactivity for the
100 and 150 kDa bands relative to that for the minor 50 kDa band in each sample [(100 + 150 kDa)/50 kDa]. The data represent the
means ± SEM and they were compared using a paired Students t test: *p <0.001. c Correlation between the levels of the 100 + 150 kDa
CSF-PS1 complexes with age
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Higher PS1 levels in demented and non-demented DS
DS is considered a pre-symptomatic AD [10]. To assess
whether an increase in the CSF-PS1 complexes is also
associated with DS, we analyzed CSF samples from DS
patients with (dDS) or without (ndDS) signs of clinical
dementia, comparing these to age-matched yNC (Fig. 4a).
The cumulative immunoreactivity of the major 100
and 150 kDa bands was significantly higher in both
dDS (p <0.001) and ndDS (p = 0.007) CSF than in
that from yNC subjects (Fig. 4b). Remarkably, the
CSF-PS1 complexes quotient also revealed consistent
changes in the proportion of the different complexes
for both dDS (p <0.001) and ndDS subjects (p = 0.04)
relative to yNC (Fig. 4b).
The formation of stable CSF-PS1 complexes is favored by
β-amyloid
Although PS1 clearly forms native complexes in CSF,
there is little knowledge about the dynamics of soluble
PS1 fragment assembly into heteromeric complexes. Thus,
we monitored the assembly of soluble PS1 into complexes
in a cell model, CHO cells over-expressing wild-type
human PS1. An increase in the 29 kDa NTF of PS1 in
extracts from CHO cells transfected with human PS1
corroborated that these cells over-expressed the protein
(Additional file 1: Figure S1A). Immunoblotting of the
cell-conditioned medium revealed predominant bands of
approximately 100 and 150 kDa, and a weaker ~70 kDa
band. The amounts of these soluble PS1 complexes in-
creased in conditioned media from CHO cells transfected
with PS1 (Additional file 1: Figure S1A). CHO cells stably
transfected with PS1 and APP showed similar soluble PS1
complexes with additional 50 kDa band and monomeric
NTF (Additional file 1: Figure S1A). To ascertain the
identity of the soluble PS1 complexes in the cellular
model, we reduced PS1 expression in CHO cells stably
over expressing wild-type human PS1 with siRNA PS1.
Cells transfected with siRNA PS1 displayed decrease in
cellular PS1-NTF, but also in soluble PS1 complexes iden-
tified in cell media (Additional file 1: Figure S1A).
Fig. 2 The increase in the CSF-PS1 complexes in ADAD. a Representative blot of the PS1 complexes in the CSF samples from eight
symptomatic ADAD (syADAD), six presymptomatic mutation carriers (psADAD) and 23 younger NC controls (yNC), eight of which
were from the same families a the ADAD subjects but that did not carry mutations (black symbol; see also Table 1). b Densitometric
quantification of the accumulative immunoreactivity from the sum of the higher molecular mass PS1 complex (100 + 150 kDa). A quotient
was calculated for each sample defined as the sum of (100 + 150 kDa) immunoreactivity relative to the 50 kDa immunoreactivity: (100 +
150 kDa/50 kDa). c Six syADAD and five yNC samples were fractionated on 5–20 % sucrose density gradients to further characterize the
PS1 complexes. The fractions (collected from the top of each tube) were immunoblotted under denaturing conditions and probed for
PS1, as in (a). β-Galactosidase (G, 16.0S; ~540 kDa), catalase (C, 11.4S; ~232 kDa) and alkaline phosphatase (P, 6.1S; ~140–160 kDa) were
used as internal markers. Representative blots are shown. d The “stability” quotient was defined as the sum of the stable immunoreactive
bands that sediment close to alkaline phosphatase (~140–160 kDa; fractions 2–7), mainly the 100 and 150 kDa bands, relative to the large
unstable complexes that sediment closer to catalase (~232 kDa; fractions 8–12), and resolve mainly as 50 kDa immunoreactive bands in
Western blots. The data are the means ± SEM: *Significantly different (p <0.005) from the yNC group as assessed by the Student t or
Mann-Whitney U tests
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We also analyzed the soluble PS1 complexes in the con-
ditioned medium of PS1-transfected CHO cells and CHO
cells over-expressing PS1 and APP, using sucrose-density
gradient fractionation followed by Western blotting under
denaturing conditions (Additional file 1: Figure S1B). The
majority of the soluble PS1 in the CHO cell-conditioned
medium accumulated close to the alkaline phosphatase
marker (~140–160 kDa) and resolved as 70 kDa complexes
after denaturation, with only faint bands at 100 kDa. How-
ever, some 29 kDa monomeric PS1 was also evident, prob-
ably released from the complexes (Additional file 1: Figure
S1B). By contrast, in the medium of CHO cells over-
expressing PS1 and APP there was virtually no 29 kDa
NTF immunoreactivity, indicating that in the context of β-
amyloid over-expression, most of the soluble PS1 is stably
incorporated into complexes (Additional file 1: Figure S1B).
Fig. 3 Increase in the stable PS1 complexes in AD and MCI CSF. a Representative blot and (b) densitometric quantification of the accumulative
immunoreactivity from the sum of stable higher molecular mass PS1 complexes (100 + 150 kDa) in CSF samples from 13 sAD, 12 MCI and 17
age-matched eNC subjects. A quotient calculated as the sum of (100 + 150 kDa) immunoreactivity relative to the 50 kDa immunoreactivity: (100
+ 150 kDa/50 kDa) is also shown. c Six AD and MCI individuals, and 8 eNC subjects were fractionated on 5–20 % sucrose density gradients, and
probed with the PS1 antibody under denaturing conditions. The internal markers were β-galactosidase (G), catalase (C) and alkaline phosphatase
(P), as in Fig. 3. d The values for the “stability” quotient reflecting the highly stable complexes (100 + 150 kDa immunoreactive bands sedimenting
in fractions 2–7) relative to the unstable complexes (50 kDa immunoreactive bands sedimenting in fractions 8–12) is also shown. *p <0.05,
**p <0.01 as assessed by the Student t or Mann-Whitney U tests
Fig. 4 An increase in PS1 stable complexes in DS CSF. a Representative blot of PS1 complexes in CSF from 10 DS subjects with
dementia of the Alzheimer’s type (dDS), 10 DS without any sign of memory decline (ndDS) and 23 yNC. b Densitometric quantification
of the accumulated immunoreactivity from the sum of the higher molecular mass PS1 complex (100 + 150 kDa), and the quotient of
the (100 + 150 kDa) immunoreactivity relative to the 50 kDa immunoreactivity (100 + 150 kDa/50 kDa). The means ± SEM are shown:
*p <0.005, **p <0.005, Student t test
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We further tested the possible interaction between
soluble PS1 complexes and Aβ. PS1 was immunoprecipi-
tated from the medium of CHO cells over-expressing PS1
and APP with the 00/2 antibody that recognizes the PS1
CTF. Immunoprecipitation of heteromeric PS1 complexes
was confirmed in Western blots probed with the anti-N-
terminal 98/1 antibody (Additional file 1: Figure S1C).
Considerable amounts of Aβ oligomers were also detected
in these immunoprecipitates by the 6E10 antibody (Add-
itional file 1: Figure S1C), while no immunoreactivity was
resolved by a C-terminal APP antibody (not shown); indi-
cating that oligomers of Aβ, but not C-terminal fragments,
interact with the soluble PS1 complexes.
To confirm that Aβ oligomers favors the formation of
stable PS1 complexes in human CSF we examined the
Aβ peptides in PS1 complexes immunoprecipitated from
CSF samples from sAD and eNC subjects. Again, CSF
samples immunoprecipitated with 00/2 antibody were
probed in immunoblots with the 98/1 and 6E10 anti-
bodies (Fig. 5a), demonstrating that Aβ oligomers co-
immunoprecipitated with heteromeric PS1 complexes
from both eNC and sAD CSF samples. We further
tested the involvement of Aβ on the formation of the
highly stable PS1 complexes. After CSF-PS1 complexes
were fractioned by sucrose density gradients and the
peak fractions of the highly stable and unstable com-
plexes were isolated, they were immunoprecipitated with
the 00/2 antibody (Fig. 5b). Aβ oligomers were clearly
present in the fractions rich in stable 100–150 kDa
complexes from both eNC and sAD samples, whereas
Fig. 5 Aβ oligomers are present in highly stable CSF-PS1 complexes. a CSF samples from eNC and sAD subjects were precleared with protein
A-Sepharose (T: total), and then immunoprecipitated with the anti CTF-PS1 00/2 antibody. The precipitated proteins (IP) were probed in
immunoblots with the antibody indicated (98/1 for NTF-PS1 and 6E10 for Aβ). Note that oligomeric Aβ species co-immunoprecipitate and
interact with CSF-PS1 complexes in both eNC and sAD. None immunoreactivity was resolved in negative controls incubated with beads in
the absence of antibody (not shown). b CSF-PS1 complexes were fractionated by sucrose gradient centrifugation, and the fractions containing highly
stable (Hs) or unstable (Us) PS1 complexes were pooled, dialyzed and concentrated by ultrafiltration. Representative sedimentation profiles illustrate
the fractions selected for peak isolation. The enriched CSF-PS1 complexes were then immunoprecipitated with the 00/2 antibody and assayed in
immunoblots probed with the 6E10 antibody against Aβ (insert). Representative blots reveal that Aβ oligomers are mainly present in peak fractions
containing highly stable PS1 complexes (illustrative examples from two different experiments)
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virtually no Aβ immunoreactivity was detected in the
pooled fractions of 50 kDa PS1 complexes (Fig. 5b).
Hence, oligomers of Aβ appear to mainly associate with
the highly stable PS1 complexes.
Discussion
The detection of soluble PS1 in CSF and serum [12] was
a somewhat unexpected finding, particularly since PS1 is
a multi-pass transmembrane protein with several hydro-
phobic regions [14]. Indeed, the presence of soluble PS1
has been reported in the medium of primary neurons
[25] and confirmed in human serum [26]. Here, we
corroborated the existence of different PS1 complexes in
human CSF and we revealed their potential utility as a
biomarker for AD. Like many membrane proteins, PS1
has a tendency to aggregate under non-native conditions
[27, 28]. Thus, CSF-PS1 complexes probably represent
non-specific aggregates of PS1 NTF and CTF distinct to
the active γ-secretase membrane-complexes [12].
How PS1 complexes become soluble and appear in the
CSF is yet to be determined. However, it appears that
Aβ oligomers can probably contribute to the formation
of stable CSF-PS1 complexes which are particularly
abundant in AD. Indeed, it is remarkable that when we
follow the formation of PS1 complexes in the cell-
conditioned media, the co-expression of APP and PS1
favored the accumulation of complexes and not soluble
monomeric PS1 is existent. We were able to pull down
oligomeric Aβ species by PS1 immunoprecipitation from
the medium, as well as from human CSF, in which Aβ
oligomers are mainly associated to the highly stable PS1
complexes. Aβ peptides are chemically “sticky”, gradually
building up into fibrils and aggregates; although the
mechanism of how can Aβ stabilize CSF-PS1 is yet to be
determined. Also in this context, levels of soluble Aβ
peptide assessed by ELISA determinations appear con-
sistently decreased in AD CSF [11]. The possibility that
some amounts of Aβ participate within stable protein
complexes in CSF, resulting underestimated by conven-
tional ELISA protocols, may deserve consideration.
In CSF samples from NC subjects we observe an age-
related increase in the total amount of PS1, while the
relative proportion of the different complexes remains
unaltered. No changes were observed comparing NC
samples from different center of sample collection or
gender. However, the relative proportion of stable PS1
complexes does appear to increase in the AD condition.
We propose that the most significant phenomenon
related to the potential use of CSF-PS1 to discriminate the
pathological state is the change in the proportion of PS1
complexes, rather than the estimates of the total PS1 levels.
Accordingly, we focused our analysis on the highly stable
100–150 kDa PS1 complexes in CSF. The highly stable
CSF-PS1 complexes co-exist with unstable complexes,
sedimenting after differential centrifugation in regions
closer to 200–250 kDa, but mainly resolved as 50 kDa
components by reducing SDS-PAGE. We found that a quo-
tient of PS1 complexes can discriminate all pathological
groups from age-matched controls. We suggest that these
quotients reflect differences in the properties of the PS1
complexes formed under pathological conditions. Screening
large numbers of samples by sucrose gradient ultracentrifu-
gation is difficult. As a reliable alternative, we addressed the
discrimination of samples using a complementary param-
eter, a quotient of CSF-PS1 complexes calculated directly
from Western blot analysis [(100 + 150 kDa)/50 kDa],
thereby simplifying the analysis. This alternative quotient is
useful to discriminate ADAD and DS subjects from age-
matched yNC, as well as sAD from eNC. In our analysis,
this quotient of PS1 complexes only failed to adequately
discriminate MCI subjects, maybe indicating a lack of sens-
ibility with respect to the evaluation of the complexes after
separation by ultracentrifugation in sucrose density gradi-
ents. The inherent uncertainty in clinical diagnosis may also
account for these differences, particularly for MCI group in
which some subjects maybe remained MCI stable or
develop to other dementias.
Anyhow, large overlap is observed between groups when
assessment of the relative amount of CSF-PS1 complexes is
estimated by a quotient obtained directly from Western
blot analysis, without fractioning by ultracentrifugation. It
will be necessary to replicate these finding using other tech-
niques, such as ELISA specific for stable CSF-PS1 com-
plexes, to evaluate their true potential as biomarkers.
Interestingly, altered levels of CSF-PS1 are detectable in
both symptomatic and asymptomatic ADAD subjects.
Similarly, alterations to CSF-PS1 levels occur in DS sub-
jects with and without dementia. The analysis of CSF sam-
ples from DS subjects is of particular interest since it is
well known that almost all adults with DS over 40 years of
age display AD neuropathology [29, 30], although the
prevalence of dementia in these individuals varies consid-
erably [31–34]. Thus, there is no association between the
age of onset of AD neuropathology in DS subjects and the
appearance of clinical dementia [35], and we cannot pre-
dict the number of ndDS that will develop future cognitive
impairment. In the view of the consistent changes in CSF-
PS1 in ndDS we assume that this biomarker is more re-
lated to the brain pathological status than the occurrence
of dementia and cognitive decline.
Conclusions
In conclusion, our present findings demonstrate that
CSF-PS1 complexes are altered in genetically determined
AD, as well as in sAD. Together, our results indicate that
the increase in stable PS1 complexes in CSF is an early
phenomenon associated to AD pathology and may
constitute an asymptomatic biomarker.
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Additional file
Additional file 1: Figure S1. Aβ affects the dynamics and stability of
the soluble PS1 complexes. (A) CHO cell were transfected with human
PS1 or with the pcDNA3 expression plasmid as a control (Ø). CHO cells
stably over-expressing PS1 and APP were also transfected with PS1 siRNA.
PS1 in the cell extracts and soluble PS1 complexes in the medium were
assayed in Western blots using a NTF-PS1 antibody (equivalent amounts
of protein of the cell extracts and equal volumes of medium were loaded
in each lane). GAPDH served as a loading control for cellular extracts. (B)
Soluble PS1 complexes from the medium conditioned by CHO cells
transfected with PS1 (CHO-PS1), or CHO cells over-expressing PS1 and
APP (CHO-PS1/APP), characterized by ultracentrifugation on 5–20 %
sucrose density gradients. Fractions were collected from the top of each
tube and they were analyzed by SDS-PAGE under denaturing conditions.
Enzymes of known sedimentation coefficient were used as internal
markers: β-galactosidase (G, 16.0S; molecular mass ~540 kDa), catalase
(C, 11.4S; ~232 kDa) and alkaline phosphatase (P, 6.1S; ~140–160 kDa).
Note that both PS1 complexes and 29 kDa monomers were identified in
CHO-PS1 cells, while the 29 kDa monomers are mostly absent from the
CHO-PS1/APP cells. (C) Cell medium conditioned by CHO-PS1/APP cells
was precleared with protein A-Sepharose and the soluble PS1 complexes
were immunoprecipitated with the anti-PS1 antibody 00/2 raised against
the CTF. The immunoprecipitated proteins (IP) were probed with the 98/
1 antibody against the NTF of PS1 and the 6E10 antibody against Aβ
(T: total). The PS1 antibody confirms the immunoprecipitation of heteromeric
complexes of PS1 and the 6E10 confirms that these PS1 complexes contain or
interact with small Aβ oligomers. Illustrative examples from three different
experiments are shown. (TIF 2441 kb)
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